A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
- Conditions
- schizophrenia
- Registration Number
- JPRN-jRCT2080222584
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
Plasma aripiprazole concentrations after repeated administration of aripiprazole IMD into the deltoid muscle were considered to have reached the steady state before the fourth dose. Repeated administration of aripiprazole IMD 400 mg into the deltoid muscle once every 4 weeks did not pose any major safety concerns.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 17
(1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR (295.30, 295.10, 295.20, 295.90, 295.60)
(2) Patients who have provided written informed consent by themselves (If the patient is a minor, written consent from a legal representative must be obtained in addition to the patient's own written informed consent.)
(3) Patients, both male and female, aged 18 years or older, but younger than 65 years, at the time of obtaining informed consent
(4) Patients with a body mass index of 18.5 or higher and lower than 35.0
(5) Patients whose mental condition is stable or well maintained for 2 weeks or more without any change to dosage regimen for their non-aripiprazole oral atypical antipsychotic monotherapy prior to obtaining informed consent
(6) Patients who have received aripiprazole in the past
(1) Patients diagnosed as having a mental disorder other than schizophrenia, as defined by DMS-IV-TR criteria.
(2) Patients with a history or complication of diabetes.
(3) Patients with hepatic, renal, cardiac, or hematopoietic disorders.
(4) Female patients who are pregnant or lactating, who may possibly be pregnant, who wish to become pregnant, or male patients whose partner wishes to become pregnant.
(5) Patients who have a drug allergy or drug hypersensitivity
(6) Patients for whom clozapine has been ineffective, patients who have responded only to clozapine, or patients who are currently being treated with clozapine.
(7) Patients with a complication of Parkinson's Disease (excluding drug-induced Parkinsonism).
(8) Patients with a history or a complication of neuroleptic malignant syndrome, rhabdomyolysis, tardive dyskinesia, paralytic ileus or water intoxication.
(9) Patients with a history or a complication of psychological or behavioral abnormalities associated with use of psychoactive substances (abuse of alcohol, narcotics, or organic solvent, etc).
(10) Patients with a history or a complication of suicide attempt or self-injury within 52 weeks prior to obtaining informed consent.
(11) Patients with a history of or a complication of convulsive disorder such as epilepsy.
(12) Patients with a history of or a complication of organic brain disorder including cerebrovascular disease.
(13) Patients with a history or a complication of granulocytopenia or agranulocytosis.
(14) Patients who have received electro-convulsive therapy (ECT) within 12 weeks prior to obtaining informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>pharmacokinetics<br>Pharmacokinetics, Safety
- Secondary Outcome Measures
Name Time Method